Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

(Photo: Rolf Vennenbernd/picture alliance via Getty Images)

Americans pay more than other countries do for prescription drugs, and see quicker drug approvals — but not necessarily better health outcomes, according to several studies.

Why it matters: As Washington debates the administration’s new Medicare drug pricing proposal, the pharmaceutical industry says high U.S. drug prices are justified because we have better access to new drugs. But if the difference isn't meaningful, or if people can't afford these new drugs, it raises the question of why we pay so much more.

The big picture: There’s no question that the U.S. is paying more for drugs than other countries, that we approve drugs faster here than Europe and Canada do, or that the development of new, expensive drugs has had medical value.

  • The questions are whether we get better health outcomes in return for what we’re paying, and whether making U.S. prices align with what other countries pay would have a negative impact on access or outcomes.

Driving the news: The Trump administration has proposed tying Medicare Part B reimbursement rates to what other countries pay for drugs.

  • PhRMA, the industry's leading trade group, says that would hurt people's access to the best medicines. It published a chart comparing the availability of cancer medications in 14 countries, which shows that the U.S. has the most available medicines and that they're available fastest.
  • The administration is proposing to piggyback off of countries that "set prices artificially low, resulting in severe access restrictions for patients," PhRMA wrote.

The other side: Some experts question the logic of PhRMA's argument.

  • "What is the implication here? That if the U.S. pays lower prices then drugs will come on the market more slowly here? Why would drug companies delay entry to the U.S. market?" said Peter Bach, of Memorial Sloan-Kettering Cancer Center.

Details: The U.S. pays more for prescription drugs — as well as health care generally — but has worse health outcomes than other countries. A 2017 Commonwealth Fund report ranked the U.S. last in health care outcomes, compared to 10 other wealthy countries.

  • In 2017, the U.S. approved more drugs than the E.U. did; 36 drugs were approved in both countries, 52 were only approved in the U.S. and 15 were only approved in the E.U., according to the NDA Group. But “some drugs that were approved in only one jurisdiction will be approved relatively quickly in the other jurisdiction but others might be delayed,” the American Enterprise Institute’s Alex Brill said.
  • The Food and Drug Administration reviews applications for novel drugs more quickly than its European and Canadian equivalents, according to a 2012 New England Journal of Medicine study. But these drugs often only reach the American market first by a matter of months.
  • A 2016 Health Affairs study found that while the U.S. accounted for 55.8% of all cancer drug spending in 2014 in the nine countries it evaluated, it only received 12.6% of the total economic value gained by saving lives through cancer treatment that year.
  • "Although the United States consistently outspent other countries on cancer drug care in the study period, it also witnessed one of the smallest improvements in cancer-related health outcomes," the study concluded.

The bottom line: This all suggests that the extra money we're spending on prescription drugs isn't producing a proportionate improvement in relative health, even if we do approve drugs faster than other countries.

Go deeper

Ina Fried, author of Login
21 mins ago - Technology
Column / Signal Boost

Huawei sanctions snarled chip supply chains

Illustration: Sarah Grillo/Axios

The largely successful U.S. effort to hobble China's Huawei has benefitted a host of other tech companies — from smartphone makers such as Apple and Xiaomi to chipmakers like Qualcomm to network vendors including Nokia and Ericsson.

Yes, but: The massive disruption to the industry furthered an industry wide mismatch between supply and demand, exacerbating the global chip shortage.

Tina Reed, author of Vitals
41 mins ago - Health

Overturning Roe could strain abortion access even in blue states

The Supreme Court is reflected in a woman's sunglasses during a march Oct. 2. Photo: Andrew Caballero-Reynolds/AFP via Getty Images

If the Supreme Court overturns Roe v. Wade, abortions could be harder to access even in states where they remain legal, because those clinics could be flooded with patients from states that have cracked down.

The big picture: This has happened before, and clinics fear the crush of demand would be a major problem in the immediate wake of a decision that would allow states to ban abortion.

A critical race theory founder says he's being inundated with threats

Richard Delgado. Photo: Courtesy of Richard Delgado

Richard Delgado, one of the founders of the critical race theory movement, tells Axios he and his wife have been receiving a steady stream of threatening messages since the coordinated, conservative campaign against critical race theory began.

Why it matters: Educators across the country — even some elementary school teachers — have faced harassment and threats over the past year over lesson plans that teach about system racism in the U.S.